FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Summary
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with ...
Description
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with ...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source